No abstract

background: The management of gastric adenocarcinoma is essentially based on surgery followed by adjuvant treatment. adjuvant chemotherapy (cT) as well as chemoradiotherapy (cTrT) have proven their effectiveness in survival outcomes compared to surgery alone. however, there is little data comparing the two adjuvant approaches. This study aimed to compare the prognosis and survival outcomes of patients with gastric adenocarcinoma operated and treated by adjuvant radiochemotherapy or chemotherapy Materials and methods: We retrospectively evaluated 80 patients with locally advanced gastric cancer (LGc) who received adjuvant treatment. We compared survival outcomes and patterns of recurrence of 53 patients treated by cTrT and those of 27 patients treated by cT. results: after a median follow-up of 38.48 months, cTrT resulted in a significant improvement of the 5-year pFs (60.9% vs. 36%, p = 0.03) and the 5-year Os (55.9% vs. 33%, p = 0.015) compared to adjuvant cT. The 5-year Os was significantly increased by adjuvant cTrT (p = 0.046) in patients with lymph node metastasis, and particularly those with advanced pN stage (p = 0.0078) and high lymph node ratio (LNr) exceeding 25% (p = 0.012). also, there was a significant improvement of the pFs of patients classified pN2-N3 (p = 0.022) with a high LNr (p = 0.018). cTrT was also associated with improved Os and pFs in patients with lymphovascular and perineural invasion (LVI and pNI) compared to chemotherapy. conclusion: There is a particular survival benefit of adding radiotherapy to chemotherapy in patients with selected criteria such as lymph node involvement, high LNr LVI, and pNI.

No abstract

Background: Endometrial cancer (EC) is the most common pelvic gynecological cancer. The purpose of the present study is to identify histoprognostic risk factors for lymph node involvement, evaluate the impact of lymphadenectomy on relapse and overall survival and assess prognostic factors influencing the survival rates in endometrial cancer.Methods: This was a retrospective study of 249 cases of endometrial cancer, over a period of 16 years (2000-2015). We analyzed the clinical, pathological features and outcome of our patients. Curves of overall and recurrence-free survival were performed.Results: In our cohort, stage IA was found in 46.6% of cases, stage IB in 14.5%, stage II in 13.7%, stage IIIA in 3.6%, stage IIIB in 2%, stage IIIC1 in 8.8%, stage IIIC2 in 4.4% and stage IV in 6.4%. The histologic type (p=0.02, OR=2.702, CI [1.169; 6.25]), myometrial invasion (p<0.001, OR=4.524, CI [1.960; 10.416]), lymphovascular space invasion (p=0.047, OR=2.267; CI [1.013; 5.076]) were the only independent factors of lymph node invasion in multivariate analysis. 5-years overall and recurrence free survival was 76.3% and 81.5%, respectively. Overall survival at 5 years was 64.6% with a lymph node ratio of less than 10%, 22.2% with a lymph node ratio between 10 and 50%, and zero with a lymph node ration greater than 50% (p=0.016). By studying the number of lymph nodes removed during lymphadenectomy, survival trend to be improved when the lymph node count increased.Conclusions: The lymphadenectomy has an incontestable diagnostic and prognostic value. Present retrospective study showed the therapeutic interest of lymph node dissection in endometrial cancers.

No abstract